臨床婦人科産科69巻1号

2015年01月発行

今月の臨床 ゲノム時代の婦人科がん診療を展望する─がんの個性に応じたpersonalizationへの道 【総論】

1．ゲノム解析に基づく婦人科がん治療を展望する

著者： 小西郁生¹

所属機関： ¹京都大学大学院医学研究科婦人科学産科学

ページ範囲：P.6 - P.14

●がんのゲノム解析に基づく個別化治療（precision medicine）が求められている．

●個別化を目指す多様な視点─がん微小環境，がん免疫，がん幹細胞─を探求する必要がある．

参考文献

1） 小西郁生 : ゲノム解析に基づく治療個別化Precision Medicineへの展望．産婦の実際63 : 893─898, 2013

2） Kharma B, et al : STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res, 2014［Epub ahead of print］

3） Horiuchi A, et al : Toward understanding the natural history of ovarian carcinoma development : a clinicopathological approach. Gynecol Oncol 88 : 309─317, 2003

4） Vang R, et al : Ovarian low-grade and high-grade serous carcinoma : Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16 : 267─282, 2009

5） The Cancer Genome Atlas Network : Integrated genome analysis of ovarian carcinoma. Nature 474 : 609─615, 2011

6） Winterhoff BJN, et al : Bevacizumab and improvement of progression-free survival（PFS） for patients with the mesenchymal subtype of ovarian cancer. 2014 ASCO Annual Meeting Proceedings（＃5509）. J Clin Oncol 32 : 15S, p353s, 2014

7） 松村謙臣，他 : 遺伝子発現解析に基づく卵巣癌の薬剤選択を目指して．日婦腫瘍会誌32 : 203─210, 2014

8） Abiko K, et al : PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19 : 1363─1374, 2013

9） Hamanishi J, et al : Efficacy and safety of anti-PD-1 antibody（Nivolumab : BMS-936558, ONO-4538）in patients with plarinum-resistant ovarian cancer. 2014 ASCO Annual Meeting Proceedings（＃5511）. J Clin Oncol 32 : 15S, p353s, 2014

10） Yamaguchi K, et al : Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29 : 1741─1752, 2010

11） Matsumura N, et al : Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 101 : 2658─2663, 2010

12） Koshiyama M, et al : Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer Biol Ther 15 : 22─25, 2014

13） Mabuchi S, et al : mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15 : 5404─5413, 2009

14） Imai T, et al : Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163 : 1437─1447, 2003

15） Kikuchi N, et al : Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma : An important autocrine/paracrine factor for tumor progression. Cancer Sci 97 : 1061─1069, 2006

16） Horiuchi A, et al : Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1 alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer 131 : 1755─1767, 2012

17） Yamamura S, et al : The activated transforming growth factor-beta signaling pathway in peritoneal metastasis is a potential therapeutic target in ovarian cancer. Int J Cancer 130 : 20─28, 2012

18） Matsumura N, et al : Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 21 : 74─82, 2011